Clinical data | |
---|---|
Other names | ASP-1707 |
Routes of administration | By mouth |
Drug class | GnRH modulator; GnRH antagonist; Antigonadotropin |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H19F3N4O5S |
Molar mass | 544.51 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Opigolix (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis. It was also under investigation for the treatment of prostate cancer. It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.
See also
References
- ^ "Opigolix - Astellas Pharma - AdisInsight".
- Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
External links
GnRHTooltip Gonadotropin-releasing hormone receptor and gonadotropin receptor modulators | |||||
---|---|---|---|---|---|
GnRHTooltip Gonadotropin-releasing hormone receptor |
| ||||
Gonadotropin |
|
This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it. |